Brains Bioceutical Corp. ("Brains Bio"), a global life sciences company advancing a clinically validated portfolio of therapeutic and pharmaceutical programs, today announced the appointment of Dr. Priyajit "Bobby" Prasad, MBBS, FRCP, FACP, FRCPI, FASGE, MBA, as Chairman of the Company's Medical Advisory Board. The appointment signals a significant milestone in Brains Bio's evolution from a science-driven cannabinoid API and nutraceutical company into a fully integrated, late-stage drug development organization with a pipeline positioned across multiple high-value therapeutic categories.
Dr. Prasad is an internationally recognized clinical leader with more than 25 years of active practice spanning the United Kingdom, the United States, and the Gulf Cooperation Council. He most recently served as Consultant Gastroenterologist and Chair of Innovation and Business Development at Mayo Clinic Healthcare, London, and currently leads the GI Department at Mediclinic Dubai Mall. A graduate of Pembroke College, Oxford (MBA, Said Business School) and Yale University School of Medicine, Dr. Prasad holds Fellowships with the Royal College of Physicians of London, the American College of Physicians, the Royal College of Physicians of Ireland, and the American Society for Gastrointestinal Endoscopy.
Beyond his clinical career, Dr. Prasad has served as a Council Member on the World Economic Forum's Industry Agenda Council on the Future of the Health Sector and its Value in Healthcare Committee at Davos, alongside the CEOs of numerous Fortune 500 companies. He sits on the University of Pennsylvania's Penn Medicine Global Advisory Board, has contributed to the Milken Institute, and has served as a Commissioner for the Task Force on Global Advantage at the Icahn School of Medicine at Mount Sinai, New York. He is also an active member of the Global Chief Medical Officer Network alongside CMOs of Global 100 companies.
Dr. Prasad's background further encompasses deep experience in healthcare private equity, having co-authored investment memoranda, led clinical due diligence, and played a central role in a healthcare PE team that raised $1 billion in dedicated health fund capital. His expertise in digital health, AI-driven clinical workflows, and early-stage biotech positions him as an ideal architect for Brains Bio's medical strategy as the Company prepares its programs for regulatory submission and commercialization.
"Brains Bio has spent years building something genuinely rare in this industry: a scientifically de-risked, multi-program drug development platform with real clinical data behind it. Bobby's appointment is the right move at exactly the right moment. His caliber of clinical authority, his network at the highest levels of global medicine, and his track record of turning science into commercial reality will be transformative for this company. This is not a ceremonial role. Bobby will be instrumental in shaping how we advance our programs, how we engage the medical community, and how we position Brains Bio as the credible pharmaceutical force we are building it to be." — Ricky Brar, Chairman and CEO of Brains Bioceutical Corp.
About the Brains Bio Drug Development Platform
Brains Bio's drug development division is built on the Company's core capabilities in cannabinoid API manufacturing, proprietary formulation science, and an expanding portfolio of clinical-stage programs across high-prevalence, high-unmet-need indications. The platform is organized across three categories: late-stage Development Programs nearing regulatory submission; Early Market Access Programs generating pre-approval revenue through international regulatory pathways; and Discovery Programs advancing novel cannabinoid-derived New Chemical Entities (NCEs) with the Changchun Institute of Applied Chemistry.
The Company's lead Development Program, Once-Daily Methazolamide for Glaucoma, has a Special Protocol Assessment in place with the FDA and has completed its pivotal registrational study, with NDA submission targeting Q1 2026 and anticipated commercial launch by end of 2026. The program carries a formulation patent through 2037 and three years of marketing exclusivity upon approval, addressing a $3.5 billion US glaucoma drug market. A second Development Program targeting Opioid Use Disorder is being advanced with Mount Sinai through a Phase 3 NIH-funded pivotal trial, supported by approximately $18 million in non-dilutive grant funding, with a planned interim analysis in Q2 2026. A third program targeting Epilepsy via the 505(b)(2) pathway is positioned for rapid submission leveraging Brains Bio's proprietary oral solid dosage formulation.
Brains Bio's Early Market Access portfolio includes a CBD Insomnia program targeting TGA registration in Australia with submission preparation underway, a Refractory Epilepsy program partnered with Prati Donnaduzzi pursuing ANVISA approval in Brazil with ANVISA approval expected in the second half of 2026, and an Osteoarthritis topical CBD program for which a Phase II proof-of-concept trial has been completed. Each program is designed to generate commercial revenue and clinical data while the Company's larger registrational trials advance.
The Discovery division, anchored by an exclusive partnership with China's Changchun Institute of Applied Chemistry (CIAC), is generating a pipeline of proprietary modified cannabinoid NCEs with significantly enhanced pharmacological profiles relative to existing molecules, including lead compound CIAC001, which has demonstrated a greater than 30-fold improvement in therapeutic index, superior CNS penetration, and preclinical efficacy in models of neuroinflammation, opioid addiction, and Alzheimer's disease.
"What Brains Bio has assembled here is genuinely impressive. The depth of the clinical pipeline, the quality of the science, and the sophistication of the regulatory strategy are not what you typically see at this stage of a company's development. What struck me equally, beyond the science, is the caliber of the people. The senior executive team brings a rare depth of pharmaceutical industry experience. These are seasoned operators who understand drug development, regulatory strategy, and commercialization at the highest level, and that kind of executive acumen is what separates companies that have promising pipelines from companies that actually deliver medicines to patients. I have spent my career at the intersection of clinical excellence and healthcare innovation, and I am proud to be joining a Medical Advisory Board that already carries tremendous credibility, comprising world leaders in CNS and related therapeutic disciplines. My intention is to build on that foundation by bringing additional globally recognized specialists onto the board as Brains Bio advances toward its most consequential chapter. Ricky's vision for this platform is clear and his leadership has built something that very few founders achieve at this level. I look forward to working alongside him and this exceptional team to help deliver on that promise." — Dr. Priyajit "Bobby" Prasad, Chairman of the Medical Advisory Board of Brains Bioceutical Corp.
About Brains Bioceutical
Brains Bioceutical Corp. is a global cannabinoid life sciences company operating across four synergistic business lines: Pharmaceuticals, Drug Development, Nutraceuticals, and Animal Health. The Company supplies pharma-grade cannabinoid APIs and finished products to partners in over 30 countries, holds a CEP-certified manufacturing standard, and operates a growing portfolio of clinical-stage drug development programs targeting large, underserved therapeutic markets. Brains Bio's platform is supported by deep scientific expertise, proprietary AI-driven capabilities, and strategic partnerships with leading academic medical institutions and global industry partners including DSM-Firmenich, Vitabiotics, and Boots.
Disclaimer
This press release contains forward-looking statements. Actual results may differ materially from those anticipated. Forward-looking statements are based on current expectations and involve known and unknown risks. Brains Bioceutical Corp. undertakes no obligation to update forward-looking statements.
